ALLO - Allogene Therapeutics Inc Stock Price, Fair Value and News

$1.51+0.17 (+12.69%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ALLO Price Action

Last 7 days

6.3%

Last 30 days

28.0%

Last 90 days

36.0%

Trailing 12 Months

-34.9%

ALLO RSI Chart

ALLO Valuation

Market Cap

339.3M

Price/Earnings (Trailing)

-1.6

Price/Sales (Trailing)

2.07

EV/EBITDA

-0.77

Price/Free Cashflow

-2.13

ALLO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ALLO Fundamentals

ALLO Revenue

Revenue (TTM)

114.1M

Rev. Growth (Yr)

-41.45%

Rev. Growth (Qtr)

-28.83%

ALLO Earnings

Earnings (TTM)

-212.0M

Earnings Growth (Yr)

37.55%

Earnings Growth (Qtr)

18.73%

ALLO Profitability

EBT Margin

-225.39%

Return on Equity

-67.24%

Return on Assets

-48.21%

Free Cashflow Yield

-46.85%

ALLO Investor Care

Shares Dilution (1Y)

7.18%

Diluted EPS (TTM)

-0.97

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	0	0	0	0
2023	0	0	0	0
2022	0	0	0	0
2021	0	0	0	114.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

CEO	Dr. David D. Chang M.D., Ph.D.
WEBSITE	allogene.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	359

Allogene Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Allogene Therapeutics Inc? What does ALLO stand for in stocks?

ALLO is the stock ticker symbol of Allogene Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allogene Therapeutics Inc (ALLO)?

As of Wed Dec 03 2025, market cap of Allogene Therapeutics Inc is 339.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALLO stock?

You can check ALLO's fair value in chart for subscribers.

Is Allogene Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALLO is over valued or under valued. Whether Allogene Therapeutics Inc is cheap or expensive depends on the assumptions which impact Allogene Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLO.

What is Allogene Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ALLO's PE ratio (Price to Earnings) is -1.6 and Price to Sales (PS) ratio is 2.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALLO PE ratio will change depending on the future growth rate expectations of investors.